Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Most women with HR+ breast cancer who survive at least 5 years have persisted with OAET despite the adverse effects of estrogen depletion.
Original languageEnglish
Pages (from-to)721 - 726
Number of pages6
JournalMenopause
Volume20
Issue number7
DOIs
Publication statusPublished - 2013

Cite this